Biological Information
Background Information:
I-kappa-B-alpha is a key cytoplasmic inhibitor of the NF-kappa-B/REL transcription factor complex, which regulates genes involved in inflammation, immune response, cell survival, and oncogenesis. Under basal conditions, I-kappa-B-alpha binds to NF-kappa-B/REL complexes trapping them in the cytoplasm and preventing transcriptional activation. Upon stimulation by pro-inflammatory signals I-kappa-B-alpha becomes phosphorylated and subsequently degraded, releasing RELA to translocate to the nucleus and activate transcription. Stabilizing I-kappa-B-alpha or preventing its degradation may suppress aberrant NF-kappa-B activation, offering therapeutic potential in autoimmune diseases, arthritis, asthma, inflammatory bowel disease and some cancers.
Target Class:
Ubiquitination-related
Family:
NF-kappa-B inhibitor
Sub Family:
Transcription regulator
Protein Name:
I-kappa-B-alpha
Protein Aliases:
IkB-alpha; IkappaBalpha
Accession Number:
M69043.1
UniProt Number:
P25963
Gene Name:
NFKBIA
Gene ID:
4792
Gene Aliases:
IKBA; MAD-3; NFKBI; EDAID2
Target Species:
Human
Usage
Product Type:
Enzymes
Application:
Drug Discovery & Development
Storage Conditions:
1 year at -70°C
Usage disclaimer:
These products may be covered by issued US and/or foreign patents, patent applications and subject to a Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information.
Assay Information
Assay Type:
Enzymatic
Assay Measures:
ECL
Bioassay Data
Trademark Statement:
For Research Use Only
Clinical Relevance
Therapeutic Area:
Oncology/Inflammation